Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
AI 90-DAY FORECAST
BULLISH SIGNAL DETECTED
██.█% Sign up free to reveal

Clearpoint Neuro, Inc. (CLPT) AI Forecast

Our AI detected a significant signal for Clearpoint Neuro, Inc.. Create a free account to see the exact price target.

Free account • 30-day free trial

$CLPT Bullish Signal Full forecast available

Clearpoint Neuro, Inc. (CLPT) Stock Forecast 2025


Clearpoint Neuro, Inc. (CLPT) AI Stock Price Forecast & Investment Analysis

Clearpoint Neuro, Inc. Stock Price Chart and Technical Analysis

Loading chart...

Clearpoint Neuro, Inc. (CLPT) - Comprehensive Stock Analysis & Investment Research

Deep dive into Clearpoint Neuro, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on April 4, 2026, 2:15 a.m. (UTC)

Clearpoint Neuro, Inc. Investment Summary

When evaluating whether Clearpoint Neuro, Inc. (CLPT) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Clearpoint Neuro, Inc. (CLPT) operates within the Industrial Applications and Services sector, specifically in the Surgical & Medical Instruments & Apparatus industry. The company employs approximately 104 people. With a market capitalization of $272 million, the company is a small-cap stock that may offer higher growth potential but also carries higher volatility.

Financial Performance Analysis

Our comprehensive financial analysis covers Clearpoint Neuro, Inc.'s revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Clearpoint Neuro, Inc. along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Clearpoint Neuro, Inc. is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Clearpoint Neuro, Inc.

Sign Up Free
Corporate Identity

Clearpoint Neuro, Inc. (Stock Symbol: CLPT) is a prominent company operating within the Industrial Applications and Services sector, with a specific focus on the Surgical & Medical Instruments & Apparatus industry. The company's shares are publicly traded on the Nasdaq exchange.

Leadership & Workforce

Detailed information about Clearpoint Neuro, Inc.'s leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Clearpoint Neuro, Inc....

Sector & Industry Analysis

In-depth sector dynamics and industry context for Clearpoint Neuro, Inc....

Unlock Full Company Profile

Get complete details about Clearpoint Neuro, Inc.

Sign Up Free
Revenue & Growth Analysis

Clearpoint Neuro, Inc. generates annual revenues of $36 million , representing an emerging company in its growth phase.

Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Clearpoint Neuro, Inc....

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Clearpoint Neuro, Inc....

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Clearpoint Neuro, Inc....

Unlock Financial Analysis

Get complete financial metrics for Clearpoint Neuro, Inc.

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Clearpoint Neuro, Inc.'s AI Price Forecast

Join 10,000+ investors using our 67%+ accurate AI predictions

4,000+ Stocks Analyzed
67%+ Accuracy Rate
Daily Updates
Start 30-Day Free Trial

30-day free trial • Cancel anytime

Strategic Market Position

Clearpoint Neuro, Inc. strategically competes in the highly dynamic Surgical & Medical Instruments & Apparatus marketplace. As a small-cap company, it represents an emerging market participant with potentially significant growth opportunities. Small-caps often offer greater growth potential as they capture market share and scale their operations, though this comes with higher risk and volatility. Success at this stage can lead to substantial returns for early investors who identify winning business models.

Industry Competitive Landscape

Clearpoint Neuro, Inc. competes within the Industrial Applications and Services sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency

The company currently shows negative free cash flow of $-15 million . Negative free cash flow may reflect heavy investment in growth, working capital needs, or operational challenges. This is common for high-growth companies investing aggressively but warrants attention for mature businesses.

Margin & Pricing Power Analysis

The company maintains a 89.6% gross margin which reflects exceptional pricing power and/or an asset-light business model. Gross margins at this level are typically seen in software, pharmaceuticals, or luxury goods companies where the cost of incremental production is minimal relative to selling prices. Such margins indicate significant competitive advantages protecting the company from price-based competition.

Operating margin of -117.5% demonstrates how efficiently the company converts revenues into operating profits after accounting for all operating expenses including research and development, sales and marketing, and general administrative costs. Operating margin compression relative to gross margin suggests high operating expenses that may warrant efficiency improvements or reflect necessary growth investments.

Asset Utilization Efficiency

Asset turnover ratio of 0.25x indicates lower asset turnover that may reflect the industry's capital-intensive nature or potentially underutilized assets. Companies with low turnover typically depend on strong margins to generate adequate returns on capital.

Financial Strength & Leverage

Current ratio of 14.60 demonstrates strong short-term liquidity with current assets significantly exceeding current liabilities. This provides a substantial buffer for meeting near-term obligations and handling unexpected financial needs.

Clearpoint Neuro, Inc. (CLPT) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Clearpoint Neuro, Inc. stock analysis.

Deep dive into Clearpoint Neuro, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Clearpoint Neuro, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Clearpoint Neuro, Inc.: With a P/E ratio of -23.51, the market sees the stock as potentially undervalued.

P/E Ratio -23.51x
P/B Ratio 9.71x
Market Cap $272M
EPS $-0.80
Book Value/Share $0.95
Revenue/Share $1.26
FCF/Share $-0.41
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Clearpoint Neuro, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Clearpoint Neuro, Inc.: An ROE of -35.3% indicates room for improvement in shareholder value creation.

ROE -35.3%
ROA -23.3%
ROIC -23.4%
Gross Margin 89.6%
Operating Margin -117.5%
Net Margin -354.5%
EBT Margin -91.5%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Clearpoint Neuro, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Clearpoint Neuro, Inc.: A current ratio of 14.60 indicates strong liquidity.

Current Ratio 14.60x
Quick Ratio 13.06x
D/E Ratio 0.25x
Financial Leverage 1.35x
Interest Coverage -20.2x
Working Capital $22M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Clearpoint Neuro, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Clearpoint Neuro, Inc.: Free cash flow of $-15M indicates cash challenges that need attention.

Operating Cash Flow -$15M
Free Cash Flow -$15M
FCF/Sales -87.6%
CapEx/Sales 1.8%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Clearpoint Neuro, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Clearpoint Neuro, Inc.: An asset turnover of 0.25x suggests room for improvement in asset utilization.

Asset Turnover 0.25x
Receivables Turnover 8.2x
Inventory Turnover 1.2x
Fixed Assets Turnover 6.0x
Days Sales Outstanding 45 days
Days Inventory 305 days
Payables Period 57 days
Cash Conversion Cycle 293 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Clearpoint Neuro, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Clearpoint Neuro, Inc.: With annual revenue of $36M, Clearpoint Neuro, Inc. represents a smaller but potentially high-growth operation.

Income Statement
Total Revenue $36M
Operating Income -$4M
Net Income -$13M
R&D Expense $3M
SG&A Expense $98M
Cost of Goods Sold $410K
Balance Sheet Highlights (% Of Assets)
Total Current Assets 94%
Cash & Short-term Investments 80%
Total Liabilities 26%
Short-term Debt 14%
Accounts Receivable 4%
Inventory 9%
Dividend & Shareholder Information
Shares Outstanding 29M
Growth Metrics (YoY)
EPS Growth -4.4%

Latest Clearpoint Neuro, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Clearpoint Neuro, Inc. (CLPT) stock price and investment outlook.

📰 We are currently updating our news feed for Clearpoint Neuro, Inc.. Check back soon for the latest market analysis and company updates.

Clearpoint Neuro, Inc. Competitors & Peer Analysis - Industrial Applications and Services Sector

Comparative analysis of Clearpoint Neuro, Inc. against industry peers and competitors in the Industrial Applications and Services sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
Adagio Medical Holdings, Inc. ADGM ██% $27M x 2.2x
Aethlon Medical Inc AEMD ██% $3M -0.1x 0.5x
Acutus Medical, Inc. AFIB ██% $0.00M 0.0x -0.4x
Allurion Technologies, Inc. ALUR ██% $12M -0.4x -0.3x
Autonomix Medical, Inc. AMIX ██% $4M x 0.5x
Angiodynamics Inc ANGO ██% $430M -1.4x 2.5x
Anika Therapeutics, Inc. ANIK ██% $209M -4.3x 1.5x
Artivion, Inc. AORT ██% $1.55B 158.6x 3.5x
Apyx Medical Corp APYX ██% $153M -3.5x 10.5x
Accuray Inc ARAY ██% $46M 4.5x 0.7x
Alphatec Holdings, Inc. ATEC ██% $1.68B -7.4x 135.3x
Atricure, Inc. ATRC ██% $1.42B -39.6x 2.9x
Nuo Therapeutics, Inc. AURX ██% $75M x 77.9x
Avita Medical, Inc. AVHHL ██% $22M x x
Baxter International Inc BAX ██% $8.61B -94.9x 1.4x
Beta Bionics, Inc. BBNX ██% $450M x 1.6x
Becton Dickinson & Co BDX ██% $56.54B 32.2x 2.2x
Heartbeam, Inc. BEAT ██% $50M -5.7x 19.3x
Bluejay Diagnostics, Inc. BJDX ██% $2M -0.5x 0.3x
Boston Scientific Corp BSX ██% $91.78B 31.7x 3.8x
Biotricity Inc. BTCY ██% $7M -2.7x 2.5x
Bioventus Inc. BVS ██% $610M 26.8x 3.3x
Brainsway Ltd. BWAY ██% $537M x x
Carlsmed, Inc. CARL ██% $256M x 2.6x
Cerus Corp CERS ██% $359M -13.8x 5.6x
Clearpoint Neuro, Inc. CLPT ██% $272M -23.5x 9.7x
Co-Diagnostics, Inc. CODX ██% $3M -0.7x 0.2x
Cytosorbents Corp CTSO ██% $34M -1.8x 5.8x
Cvrx, Inc. CVRX ██% $236M -5.5x 6.0x
Delcath Systems, Inc. DCTH ██% $334M 123.7x 3.0x
Dih Holding Us, Inc. DHAI ██% $70K x -0.3x
Dariohealth Corp. DRIO ██% $56M 0.6x 0.8x
Alpha Tau Medical Ltd. DRTS ██% $621M x 8.1x
Dexcom Inc DXCM ██% $23.94B 28.6x 8.7x
Dynatronics Corp DYNT ██% $540K -0.2x 0.2x
Ebr Systems, Inc. EBRCZ ██% $215M x 8.4x
Encision Inc ECIA ██% $2M x 1.2x
Embecta Corp. EMBC ██% $520M 3.7x -0.8x
Electromedical Technologies, Inc EMED ██% $750K x x
Femasys Inc FEMY ██% $25M -1.4x 4.2x
Family Office Of America, Inc. FOFA ██% $48M x 59.5x
Glucotrack, Inc. GCTK ██% $720K 0.9x 0.3x
Global Innovative Platforms Inc. GIPL ██% $320K x 2.0x
Glaukos Corp GKOS ██% $6.48B -46.3x 9.9x
Globus Medical Inc GMED ██% $11.86B 22.1x 2.6x
Fractyl Health, Inc. GUTS ██% $71M x 7.5x
Haemonetics Corp HAE ██% $2.63B 15.0x 2.9x
Harvard Apparatus Regenerative Technology, Inc. HRGN ██% $29M x 27.9x
Heartflow, Inc. HTFL ██% $2.09B x 7.0x
Integra Lifesciences Holdings Corp IART ██% $734M 200.2x 0.7x
Icecure Medical Ltd. ICCM ██% $24M x 2.7x
Seastar Medical Holding Corp ICU ██% $88M -1.1x 7.7x
Icu Medical Inc/De ICUI ██% $3.09B 4223.3x 1.5x
Interpace Biosciences, Inc. IDXG ██% $56M 2.3x 2.5x
Inspira Technologies Oxy B.H.N. Ltd IINN ██% $20M x 8.5x
Inspira Technologies Oxy B.H.N. Ltd IINNW ██% $7M x 1.5x
Intelligent Bio Solutions Inc. INBS ██% $6M -0.3x 0.6x
Infusystem Holdings, Inc INFU ██% $169M 30.5x 3.0x
Inspire Medical Systems, Inc. INSP ██% $1.53B 10.5x 2.0x
Iradimed Corp IRMD ██% $1.23B 54.9x 13.0x
Irhythm Holdings, Inc. IRTC ██% $3.82B -20.2x 25.0x
Invo Fertility, Inc. IVF ██% $18M x 3.1x
Orthopediatrics Corp KIDS ██% $409M -20.7x 1.2x
Kestra Medical Technologies, Ltd. KMTS ██% $1.17B x 4.1x
Koru Medical Systems, Inc. KRMD ██% $198M -19.8x 11.6x
Lemaitre Vascular Inc LMAT ██% $2.48B 42.9x 6.3x
Lensar, Inc. LNSR ██% $72M -6.7x 14.7x
Lucid Diagnostics Inc. LUCD ██% $196M -0.6x 17.9x
Pulmonx Corp LUNG ██% $53M -4.3x 1.0x
Lyra Therapeutics, Inc. LYRA ██% $870K -0.1x 0.5x
Microbot Medical Inc. MBOT ██% $159M -1.3x 2.1x
Mountain Crest Acquisition Corp. V MCAG ██% $34M x 1509.8x
Mountain Crest Acquisition Corp. V MCAGU ██% $31M x -9.9x
Spectral Ai, Inc. MDAI ██% $44M -1.3x 30.8x
Medinotec Inc. MDNC ██% $59M 25.1x 10.7x
Mimedx Group, Inc. MDXG ██% $585M 12.0x 2.3x
Monogram Technologies Inc. MGRM ██% $217M -10.7x 25.1x
Meihua International Medical Technologies Co., Ltd. MHUA ██% $151M x 0.9x
3m Co MMM ██% $77.02B 23.7x 16.4x
Merit Medical Systems Inc MMSI ██% $4.05B 31.6x 2.6x
Modular Medical, Inc. MODD ██% $25M -2.1x 4.3x
Nephros Inc NEPH ██% $32M 26.4x 3.1x
Neuroone Medical Technologies Corp NMTC ██% $40M -1.7x 6.3x
Neuropace Inc NPCE ██% $492M -10.4x 25.9x
Inspiremd, Inc. NSPR ██% $68M -4.3x 1.2x
Nu-Med Plus, Inc. NUMD ██% $930K x 4.8x
Novocure Ltd NVCR ██% $1.18B -20.8x 3.5x
Envveno Medical Corp NVNO ██% $7M x 0.3x
Nexgel, Inc. NXGL ██% $5M -6.8x 1.1x
Nyxoah Sa NYXH ██% $136M x x
Orchestra Biomed Holdings, Inc. OBIO ██% $248M -3.4x 4.6x
Odyssey Health, Inc. ODYY ██% $6M x 0.8x
Orthofix Medical Inc. OFIX ██% $459M -5.8x 1.0x
Osr Holdings, Inc. OSRH ██% $16M x 0.2x
Orasure Technologies Inc OSUR ██% $215M 17.1x 0.6x
Pavmed Inc. PAVM ██% $15M 36.5x 0.4x
Pro Dex Inc PDEX ██% $164M 14.4x 3.9x
Penumbra Inc PEN ██% $12.90B 72.6x 9.0x
Petvivo Holdings, Inc. PETV ██% $24M -1.4x 7.1x
Profusa, Inc. PFSA ██% $790K x x
Polyrizon Ltd. PLRZ ██% $20M x 1.0x
Pulse Biosciences, Inc. PLSE ██% $1.56B -2.6x 19.4x
Picard Medical, Inc. PMI ██% $71M x 18.8x
Insulet Corp PODD ██% $14.57B 59.0x 9.6x
Procept Biorobotics Corp PRCT ██% $1.43B -45.4x 3.9x
Premier Air Charter Holdings Inc. PREM ██% $2M x 2.1x
Profound Medical Corp. PROF ██% $237M x 3.6x
Plus Therapeutics, Inc. PSTV ██% $28M -0.3x 7.1x
Polypid Ltd. PYPD ██% $80M x 7.3x
Avita Medical, Inc. RCEL ██% $115M -5.0x 25.2x
Vivos Inc RDGL ██% $41M x 24.6x
Resmed Inc RMD ██% $32.46B 21.9x 5.1x
Resmed Inc RSMDF ██% $3.82B 2.7x 0.6x
Retinalgenix Technologies Inc. RTGN ██% $60M x x
Retractable Technologies Inc RVP ██% $20M -0.9x 0.3x
Sight Sciences, Inc. SGHT ██% $196M -3.7x 3.1x
Si-Bone, Inc. SIBN ██% $568M -14.3x 3.2x
Sigyn Therapeutics, Inc. SIGY ██% $50K x 0.1x
Sintx Technologies, Inc. SINT ██% $10M x 3.4x
Beauty Health Co SKIN ██% $118M -1.8x 1.9x
Sonoma Pharmaceuticals, Inc. SNOA ██% $4M -5.6x 1.2x
Sanuwave Health, Inc. SNWV ██% $146M 12.4x 90.3x
Solventum Corp SOLV ██% $11.16B 7.2x 2.2x
Sensus Healthcare, Inc. SRTS ██% $68M 31.6x 1.4x
Ss Innovations International, Inc. SSII ██% $1.01B x 26.4x
Strata Skin Sciences, Inc. SSKN ██% $1M -8.0x 0.5x
Neuronetics, Inc. STIM ██% $103M -1.0x 4.6x
Stimcell Energetics Inc. STME ██% $7M x 1152.5x
Sharps Technology Inc. STSS ██% $47M -2.5x 0.2x
Stevanato Group S.P.A. STVN ██% $3.77B x x
Stryker Corp SYK ██% $125.90B 38.8x 5.6x
Tactile Systems Technology Inc TCMD ██% $552M 28.9x 2.5x
Tela Bio, Inc. TELA ██% $25M -1.8x 4.0x
Teleflex Inc TFX ██% $5.26B 31.0x 1.7x
Trisalus Life Sciences, Inc. TLSI ██% $260M -3.6x 28.5x
Trisalus Life Sciences, Inc. TLSIW ██% $62M x -1.9x
Treace Medical Concepts, Inc. TMCI ██% $89M -7.5x 1.0x
Tandem Diabetes Care Inc TNDM ██% $1.28B -17.1x 8.3x
Tenon Medical, Inc. TNON ██% $8M -0.3x 1.5x
T2 Biosystems, Inc. TTOO ██% $210K 0.0x -0.3x
Ufp Technologies Inc UFPT ██% $1.46B 21.4x 3.5x
Qhslab, Inc. USAQ ██% $9M 20.2x 5.7x
Utah Medical Products Inc UTMD ██% $200M 17.8x 1.7x
Venus Concept Inc. VERO ██% $560K 0.0x 0.2x
Catheter Precision, Inc. VTAK ██% $2M x 0.3x
Vivos Therapeutics, Inc. VVOS ██% $15M x 5.8x
Vycor Medical Inc VYCO ██% $3M x 36.9x
West Pharmaceutical Services Inc WST ██% $18.28B 37.0x 5.8x
Beyond Air, Inc. XAIR ██% $7M -0.3x 0.9x
Xtant Medical Holdings, Inc. XTNT ██% $72M 14.4x 1.4x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Clearpoint Neuro, Inc. Stock Forecast

How accurate are Clearpoint Neuro, Inc. stock predictions?

Our AI model shows a 31% Spearman correlation coefficient for CLPT predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Clearpoint Neuro, Inc. stock price forecasts?

Our analysis considers Clearpoint Neuro, Inc.'s financial metrics, Industrial Applications and Services sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Clearpoint Neuro, Inc. a good investment in 2025?

Based on our AI analysis, Clearpoint Neuro, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Clearpoint Neuro, Inc. forecasts updated?

Clearpoint Neuro, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want a simpler view of Clearpoint Neuro, Inc.?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...